Beta Cell Imaging Biomarkers for Specific Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for imaging pancreatic beta cell mass lack specific and reliable markers, leading to challenges in quantification and visualization, especially in diabetic disorders and islet transplantation, due to high background levels and non-specific binding to other tissues.
Innovation Solution
Development of biomarkers such as FXYD2-gamma-a, FXYD2-gamma-b, and FXYD2-gamma-c, specifically expressed in pancreatic beta cells, allowing for targeted imaging and quantification using labeled molecules for PET or SPECT imaging.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current imaging methods are used to visualize pancreatic beta cells, then imaging can be performed, but the specificity is low due to high background levels and non-specific binding to other tissues
Solution Approach 1:
The patent segments the imaging target from other pancreatic tissues by identifying and utilizing biomarkers (such as FXYD2-gamma isoforms) that are specifically expressed in beta cells. This segmentation allows the imaging probe to distinguish beta cells from alpha cells, delta cells, and exocrine pancreatic tissue, thereby reducing background interference and improving imaging specificity.
2Measurement precision
If non-specific markers are used for imaging, then imaging can be performed across all pancreatic tissues, but quantification of beta cell mass is inaccurate
Solution Approach 1:
The patent introduces specific beta cell membrane biomarkers as intermediaries between the imaging probe and the target tissue. These biomarkers (e.g., FXYD2-gamma-a, FXYD2-gamma-b, FXYD2-gamma-c) serve as mediators that enable selective binding of imaging probes to beta cells, allowing accurate quantification of beta cell mass without requiring complex imaging protocols or multiple probes.
3Illumination intensity
If markers with high expression in multiple pancreatic cell types are used, then signal intensity is high, but the ability to specifically identify beta cells is reduced
Solution Approach 1:
The patent applies the local quality principle by identifying biomarkers with heterogeneous expression patterns across different pancreatic cell types. Specifically, FXYD2-gamma isoforms are expressed at high levels in beta cells but at low or undetectable levels in alpha cells, delta cells, and exocrine tissues. This localized high expression in beta cells provides both strong imaging signal and high identification accuracy.
Data Source
AI summary
The present invention is directed to the identification of a biomarker specifically located in the plasma membrane of pancreatic beta cells. It was selected by a Systems Biology approach on Massively Parallel Signal Sequencing datasets obtained in human islets and Affymetrix microarray datasets on human islets, purified rat primary beta and non beta cells and insulinoma cells. Based on a set of specific features the biomarker is a unique candidate for imaging and targeting strategies to study the pancreatic beta cell mass in health and disease (T1 D, T2D, pancreatic cancers, obesity, islet transplantation, beta cell regeneration). The five specific features of the selected biomarkers are: 1) Preferentially expressed in pancreatic islets as compared to surrounding tissues; 2) Higher expression in pancreatic beta cells than in pancreatic alpha cells or than in other islet non-beta cells; 3) Expression levels in pancreatic beta cells are higher or comparable to glucokinase which is an enzyme specifically expressed in the pancreatic beta cell; 4) Located in the membrane and as such targetable with antibodies, peptides or small molecules which allows imaging, targeting and immunohistochemistry; and 5) Expression is not induced during the process of inflammation of the beta cell mass and the protein is not enriched in T-cells and dendritic cells or in other cells participating in the inflammation process.